Organisation paid for research Program year 2025 Source: CMS Open Payments

Toi Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$1,877,012

297 payments

Through program year 2025, Toi Clinical Research LLC is reported as receiving $1,877,012 in research payments, across 297 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $479,063 91
2024 Research $859,667 90
2023 Research $538,283 116

Breakdown

Who paid Research payments · program years 2023–2025
  1. AstraZeneca Pharmaceuticals LP $689,468 15 payments
  2. Genentech, Inc. $473,516 106 payments
  3. Janssen Research & Development, LLC $170,520 48 payments
  4. AstraZeneca UK Limited $148,471 12 payments
  5. Acerta Pharma LLC $106,306 7 payments
  6. Novartis Pharmaceuticals Corporation $86,085 6 payments
  7. Regeneron Pharmaceuticals, Inc. $54,792 31 payments
  8. Aadi Bioscience, Inc. $48,906 13 payments
  9. Astellas Pharma Global Development $23,904 4 payments
  10. Sobi, Inc $18,764 29 payments
Studies the money was for Research payments · program years 2023–2025
  1. Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) $587,358 5 payments
  2. Phase III Study of Giredestrant Everolimus VS Everolimus Exemestane in Er Her2 Locally Adv Or MBC $253,975 60 payments
  3. T Dm1 Atezolizumab in High Risk Her2 Patients With Residual Disease $181,941 44 payments
  4. Part 1 FL An Open label Phase 1b Study of ACP196 Alone or in Combination with Rituximab in Subjects with Follicular Lymphoma Part 2 MZL An Open label Phase 1b or 2 Study of Acalabrutinib Alone or in Combination with Rituximab in Subjects with Indolent Bcell Non Hodgkin Lymphoma $102,479 3 payments
  5. Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia $94,879 37 payments
  6. A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc $64,890 9 payments
  7. A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) $59,889 2 payments
  8. A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) $58,619 4 payments
  9. A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) $49,377 2 payments
  10. A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy $45,017 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record